Section Arrow
MESO.NASDAQ
- Mesoblast Limited
Quotes are at least 15-min delayed:2026/09/04 00:26 EDT
Regular Hours
Last
 17.14
-0.15 (-0.87%)
Day High 
17.29 
Prev. Close
17.29 
1-M High
18.33 
Volume 
86.06K 
Bid
16.97
Ask
17.22
Day Low
16.935 
Open
17.27 
1-M Low
14 
Market Cap 
2.25B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 17.13 
20-SMA 16.81 
50-SMA 15.84 
52-W High 21.5 
52-W Low 13.05 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-0.44/-0.44
Enterprise Value
2.36B
Balance Sheet
Book Value Per Share
4.38
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
120.25M
Operating Revenue Per Share
0.06
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
RAREUltragenyx Pharmaceutical14.85-11.68-44.03%-- 
AIMAIM ImmunoTech Inc.0.2337-0.0009-0.38%-- 
ATAIAtaiBeckley Inc7.34-0.01-0.14%-- 
SMMTSummit Therapeutics17.13+2.53+17.33%-- 
IOVAIovance Biotherapeutics8.7+0.08+0.93%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low backpain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.